Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 3/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10173082 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL30471287 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL15280776 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL28510322 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL29398585 | 1.00 | KMT2A (0.51) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL25359262 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL31144370 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL26008676 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL25359258 | 0.94 | KMT2A (0.54) | KMT2ACASP3PTPN1MDM4TP53 | |
| SCHEMBL5061301 | 0.92 | KMT2A (0.58) | KMT2ACASP3MDM4TP53CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | ENTRADA THERAPEUTICS, INC. | 2025-09-18 | — | — | US | claimed |
| CN-114685645-B | Synthetic method of somalupeptide | 深圳翰宇药业股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-114685645-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-122011117-A | Cyclic peptide for resisting ultraviolet injury and application thereof in cosmetics | 深圳肽盛渼生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-121426710-A | Production process of N-Fmoc-L-glutamic acid-1-allyl ester | 江苏吉泰肽业科技有限公司 | 2026-01-30 | — | — | CN | disclosed |
| CN-121426710-A | Production process of N-Fmoc-L-glutamic acid-1-allyl ester | 江苏吉泰肽业科技有限公司 | 2026-01-30 | — | — | CN | disclosed |
| EP-4624486-A1 | POLYPEPTIDE HAVING MODIFIED STRUCTURE AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250282824-A1 | Inhibitors of the Wnt Signaling Pathway and Uses Thereof | STICHTING VU (NL) | 2025-09-11 | — | — | US | disclosed |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4063380-A1 | INHIBITORS OF THE WNT SIGNALING PATHWAY AND USES THEREOF | Stichting VU (NL) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022193902-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | 亚飞上海生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114685645-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022115825-A1 | COMPOSITIONS AND METHODS FOR CHEMICAL SYNTHESIS | GAP PEPTIDES, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | YAFEI (SHANGHAI) BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220040255-A1 | CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319341-B2 | Immune-stimulating soluble doxorubicin-conjugated complex | TLR3, CD40, TLR6 | KMT2A 3466/4885CASP3 958/4885PTPN1 4678/4885 |
| US-20250282824-A1 | Inhibitors of the Wnt Signaling Pathway and Uses Thereof | WNT1, WNT3, WNT3A | KMT2A 2588/4885CASP3 1971/4885PTPN1 1555/4885 |
| US-20250243244-A1 | CYCLIC CELL PENETRATING PEPTIDES | SLC47A1, SLC47A2, VIP | KMT2A 4814/4885CASP3 148/4885PTPN1 2890/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | KMT2A 322/4885CASP3 2086/4885PTPN1 2204/4885 |
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | IAPP, LNPEP, CFTR | KMT2A 4707/4885CASP3 2302/4885PTPN1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.